Table 1.

Demographics, Biochemical Response, and Clinical Outcomes of Treated and Untreated Patients

	No Treatment (n = 51)	UDCA (n = 236)	PValue
Demographics
Age at PSC diagnosis	12.6	11.1	0.026
Inflammatory bowel disease	84%	84%	0.941
Ulcerative colitis phenotype	88%	84%	0.479
Crohn’s disease phenotype	12%	16%	0.479
Autoimmune hepatitis overlap	45%	38%	0.327
Large duct involvement	69%	75%	0.383
Laboratory studies at PSC diagnosis
GGT (U/L)	290	269	0.948
ALP (x ULN)	1.2	1.3	0.583
ALT (U/L)	175	238	0.162
APRI	0.6	1.1	0.014
Total bilirubin (mg/dL)	0.5	0.6	0.795
Laboratory studies at 1 year
GGT (U/L)	115	43	< 0.001
ALP (x ULN)	0.8	0.6	0.017
ALT (U/L)	96	62	0.003
APRI	0.5	0.4	0.031
Total bilirubin (mg/dL)	0.5	0.6	0.235
Percentage decrease in laboratory studies from diagnosis to 1 year
GGT (U/L)	60%	75%	0.002
ALP (x ULN)	12%	44%	< 0.001
ALT (U/L)	22%	73%	< 0.001
APRI	22%	58%	< 0.001
Total bilirubin (mg/dL)	0%	9%	0.322
Rate of liver outcomes within 5 years of diagnosis
Portal hypertensive complications	18%	19%	0.814
Biliary stricture requiring procedural intervention	8%	6%	0.698
Liver transplantation	12%	11%	0.807
Cholangiocarcinoma	0%	1%	0.511
Death	0%	1%	0.511
Any adverse outcome	25%	25%	0.945

Abbreviation: ULN, upper limit of normal.